Alimera Sciences Cancels IPO


Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, has withdrawn registration for a $75 million IPO, due to “current public market conditions.” It had planned to trade on the Nasdaq, with Credit Suisse and Citi serving as co-lead underwriters.

Alimera has raised just over $71 million in VC funding since 2004, from firms like Scale Venture Partners (18.27% pre-IPO stake), Domain Associates (18.27%), Intersouth Partners(18.27%), Polaris Venture Partners (18.27%) and Venrock Associates (14.8%).

It also received a total of $16.7 million from the sale of two OTC allergy products and a lubricating eye from to Bausch & Lomb. www.alimerasciences.com

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.